Castle Biosciences Company Leadership
| CSTL Stock | USD 29.51 0.30 1.01% |
Castle Biosciences' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Castle Biosciences suggests that most insiders are panicking. Castle Biosciences employs about 710 people. The company is managed by 14 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 50.71 employees per reported executive.
| Derek Maetzold CEO President CEO, Founder, Director |
| Toby Juvenal President Vice President of Sales |
Castle Biosciences' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-11-15 | Frank Stokes | Disposed 6923 @ 29.93 | View | ||
| 2024-11-12 | Derek J Maetzold | Disposed 1972 @ 34.15 | View | ||
| 2024-11-05 | Tobin W Juvenal | Disposed 3507 @ 35.56 | View | ||
| 2024-10-14 | Derek J Maetzold | Disposed 1972 @ 32.27 | View | ||
| 2024-10-08 | Derek J Maetzold | Disposed 986 @ 30.27 | View | ||
| 2024-10-07 | Daniel Bradbury | Disposed 7867 @ 29.44 | View | ||
| 2024-10-04 | Derek J Maetzold | Disposed 986 @ 28.73 | View | ||
| 2024-08-12 | Daniel Bradbury | Disposed 7883 @ 26.65 | View | ||
| 2024-08-07 | Frank Stokes | Disposed 10000 @ 25.7 | View | ||
| 2024-08-01 | Kristen M Oelschlager | Disposed 12989 @ 23.06 | View | ||
| 2024-07-29 | Kristen M Oelschlager | Disposed 2793 @ 22.06 | View | ||
| 2024-06-03 | Derek J Maetzold | Disposed 2368 @ 23.4 | View | ||
| 2024-05-06 | Derek J Maetzold | Disposed 2368 @ 24.72 | View | ||
| 2024-04-23 | Derek J Maetzold | Disposed 421 @ 20.11 | View | ||
| 2024-04-12 | Derek J Maetzold | Disposed 1947 @ 20.35 | View | ||
| 2024-04-08 | Daniel Bradbury | Disposed 2400 @ 20.45 | View | ||
| 2024-04-04 | Daniel Bradbury | Disposed 9152 @ 21.45 | View | ||
| 2024-04-03 | Derek J Maetzold | Disposed 2368 @ 21.7 | View | ||
| 2024-03-20 | Derek J Maetzold | Disposed 2295 @ 20.27 | View |
Monitoring Castle Biosciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Castle |
Castle Biosciences' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Castle Biosciences' future performance. Based on our forecasts, it is anticipated that Castle will maintain a workforce of about 710 employees by December 2024.Castle Biosciences Management Team Effectiveness
The value of Return On Tangible Assets is estimated to slide to -0.18. The value of Return On Capital Employed is expected to slide to -0.18. At this time, Castle Biosciences' Non Current Assets Total are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 2.8 M this year, although the value of Net Tangible Assets will most likely fall to about 181.4 M. Castle Biosciences' management efficiency ratios could be used to measure how well Castle Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The value of Common Stock Shares Outstanding is expected to slide to about 19.8 M. Net Loss is expected to rise to about (57.4 M) this year
Castle Biosciences Workforce Comparison
Castle Biosciences is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 12,527. Castle Biosciences holds roughly 710 in number of employees claiming about 6% of equities under Health Care industry.
Castle Biosciences Profit Margins
The company has Profit Margin (PM) of 0.02 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.06 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.06.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.63 | 0.7953 |
|
|
Castle Biosciences Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Castle Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Castle Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Castle Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 0.0476 | 2 | 42 | 4,607 | 42,214 |
| 2024-09-01 | 0.2097 | 13 | 62 | 201,953 | 95,985 |
| 2024-06-01 | 0.2542 | 15 | 59 | 121,650 | 127,442 |
| 2024-03-01 | 0.186 | 8 | 43 | 317,042 | 102,643 |
| 2023-12-01 | 0.0732 | 15 | 205 | 137,447 | 366,177 |
| 2023-09-01 | 0.0476 | 2 | 42 | 880.00 | 98,624 |
| 2023-06-01 | 0.2432 | 18 | 74 | 96,514 | 110,567 |
| 2023-03-01 | 0.0164 | 1 | 61 | 6,173 | 103,793 |
| 2022-12-01 | 0.1417 | 17 | 120 | 386,975 | 154,413 |
| 2022-06-01 | 5.0 | 25 | 5 | 179,433 | 10,146 |
| 2021-12-01 | 0.1415 | 15 | 106 | 413,939 | 113,599 |
| 2021-09-01 | 0.0226 | 6 | 266 | 28,771 | 348,302 |
| 2021-06-01 | 0.1429 | 18 | 126 | 62,430 | 1,042,240 |
| 2021-03-01 | 0.0105 | 2 | 190 | 19,729 | 575,598 |
| 2020-12-01 | 0.0514 | 9 | 175 | 204,550 | 947,623 |
| 2020-09-01 | 0.0068 | 1 | 147 | 13,000 | 981,850 |
| 2020-06-01 | 0.1458 | 14 | 96 | 196,228 | 1,637,909 |
| 2019-09-01 | 0.28 | 28 | 100 | 8,411,442 | 14,236,227 |
| 2004-09-01 | 32.0 | 32 | 1 | 156,833 | 500.00 |
Castle Biosciences Notable Stakeholders
A Castle Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Castle Biosciences often face trade-offs trying to please all of them. Castle Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Castle Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Derek Maetzold | President CEO, Founder, Director | Profile | |
| Toby Juvenal | Vice President of Sales | Profile | |
| Frank Stokes | CFO Treasurer | Profile | |
| Keli Greenberg | VP Resources | Profile | |
| Camilla Zuckero | Exec Communications | Profile | |
| John Abbott | VP Controller | Profile | |
| RN RN | Chief Officer | Profile | |
| Kristen RN | Chief Officer | Profile | |
| Tobin Juvenal | Chief Officer | Profile | |
| Kevin Doman | Vice Sales | Profile | |
| Alice Izzo | Senior Marketing | Profile | |
| Matthew MD | Senior Medical | Profile | |
| Robert Cook | Senior Development | Profile | |
| Bernhard Spiess | Company Secretary | Profile |
About Castle Biosciences Management Performance
The success or failure of an entity such as Castle Biosciences often depends on how effective the management is. Castle Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Castle management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Castle management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.17) | (0.18) | |
| Return On Assets | (0.13) | (0.13) | |
| Return On Equity | (0.15) | (0.14) |
Castle Biosciences Workforce Analysis
Traditionally, organizations such as Castle Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Castle Biosciences within its industry.Castle Biosciences Manpower Efficiency
Return on Castle Biosciences Manpower
| Revenue Per Employee | 309.6K | |
| Revenue Per Executive | 15.7M | |
| Net Loss Per Employee | 80.9K | |
| Net Loss Per Executive | 4.1M | |
| Working Capital Per Employee | 349.3K | |
| Working Capital Per Executive | 17.7M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Castle Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Castle Stock please use our How to buy in Castle Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Castle Biosciences. If investors know Castle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Castle Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.93) | Earnings Share 0.21 | Revenue Per Share 11.34 | Quarterly Revenue Growth 0.395 | Return On Assets (0) |
The market value of Castle Biosciences is measured differently than its book value, which is the value of Castle that is recorded on the company's balance sheet. Investors also form their own opinion of Castle Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Castle Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Castle Biosciences' market value can be influenced by many factors that don't directly affect Castle Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Castle Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Castle Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Castle Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.